TGFB1 and triple-negative breast carcinoma: ZL170 inhibits proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration via inhibition of TGF-β/BMP-SMAD pathways in triple-negative breast cancer (Di et al., 2019).